ArticleInternational journal of hematology2019

A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma.

Ken Ohmachi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.